Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8...

12
Folate and Arsenic Metabolism: A double -blind placebo controlled folate supplementation trial in Bangladesh. J. Richard Pilsner, MPH, MPhil Dr. Mary V. Gamble’s Laboratory Mailman School of Public Health Columbia University RO1 ES011601 & P42 ES10349

Transcript of Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8...

Page 1: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Folate and Arsenic Metabolism: A double -blind placebo

controlled folate supplementation trial in

Bangladesh.

J. Richard Pilsner, MPH, MPhil

Dr. Mary V. Gamble’s Laboratory Mailman School of Public Health

Columbia University

RO1 ES011601 & P42 ES10349

Page 2: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Arsenic metabolism by mono- and dimethylation.

O = AsV - OH HO - AsIII - OH

OH

O-

ArsenateV ArseniteIII

OH

OH

O = AsV - CH3

OH

Methylarsonic acid (MMAV)

Methylarsonous acid (MMAIII)OH

AsIII - CH3

OH

O = AsV - CH3

CH3

OH

Dimethylarsinic acid (DMAV)

GSH

GSSG

SAH SAM

GSH GSSG

SAM

SAH

AsIII - CH3

CH3

OH

Dimethylarsonous acid (DMAIII)

GSSG

GSH

Page 3: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Overview of One-Carbon Metabolism

Homocysteine

Methionine

SAM

SAH

Cystathionine

Cysteine + Glutamate

serine

Transsulfuration Pathway

-

GSH GSSGAs(V) As(III)

MMA(V) MMA(III)

Folate

10 formyl THF

THF

5 Methyl THF

5:10 Methylene-THF

Serine

Glycine

purine synthesis

thymidylatesynthesis

DHF

γ-glutamylcysteine + Glycine

InAs

MMA

DMA

Tot

al u

rina

ry a

rsen

ic

Page 4: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Background: Arsenic Methylation & Folate

• Animal studies• Dietary folate deficiency

• Toxicol.Lett. 2003: 145:167-74

• Dietary methyl donor deficiency• Mutat Res 1997: 386:315-34

• Case-control studies in Taiwan• Lower DMA in urine increased the risk of skin and

bladder cancers and peripheral vascular disease

Decrease total urinary arsenic

excretion, particularly DMA

J Occup environ Med 2003, 45:241-8Cancer Epidemiol Biomarker Prev 1997: 589-96Toxicol Appl Pahrmacol 2005, 206: 299-308

Page 5: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Background: Arsenic Methylation in Bangladesh

• Prospective cohort• Increase %MMA in urine is a risk factor for skin

lesions

• Cross-Sectional Study

%InAs %MMA %DMAFolate (nM) -0.12* -0.12* 0.14*Homocysteine (µM) 0.06 0.21# -0.14**Spearman correlation coefficients * p < 0.05, ** p < 0.001, # p < 0.001

Environ Health Perspect 2005, 113:1683-88

Page 6: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Placebo-controlled Folate Intervention Trial

Hypothesis

Folate supplementation to folate deficient Bangladeshi adults enhances

the methylation of arsenic.

Page 7: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Study Design: Placebo-controlled Folate Intervention Trial

• 200 folate-deficient Bangladeshi adults• (Plasma folate < 9 nM)

• 12 weeks: Folic Acid (400 µg/d) or placebo

• Urinary As metabolites analyzed:• 0, 1, & 12 weeks

• All participants received a supply ofmultivitamins upon completion of the study

Page 8: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Results: Nutritional Parameters Pre- and Post-Intervention

Folate

0102030405060708090

100

Pre Post

Fola

te (n

mol

/L)

Homocysteine

0

3

6

9

12

15

18

21

Pre PosttH

cys

(um

ol/L

)Folate (n= 96)

Placebo (n=98)

a,b

a,c

a: p < 0.0001 within group; b: p < 0.0001 between groups; c: p < 0.001 between groupsWilcoxon rank sum test for continuous variables

Page 9: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Results: Effects of Folate Supplementation on Arsenic Metabolites in Urine

%InAs

Week0 2 4 6 8 10 12

10

12

14

16

18 %MMA

Week0 2 4 6 8 10 12

9

10

11

12

13

14

15

FolatePlacebo

%DMA

Week0 2 4 6 8 10 12

70

72

74

76

78

80

82

Folate (n=96)Placebo (n=98)

Perc

ent

Perc

ent

Perc

ent

##

#

*

***

**

**

Week Week Week

*p < 0.05; ** p < 0.001 (folate vs. placebo); # p < 0.05 (placebo pre- vs. post intervention)Repeated measures linear regression

Page 10: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Distribution of %DMA in Urine after 12 Weeks Folate or Placebo Supplementation

0

5

10

15

20

25

30

35

40

50 55 60 65 70 75 80 85 90 95%DMA

Freq

uenc

y (N

)

Placebo Folate

50 55 60 65 70 75 80 85 90 95

%DMA

Fre

qu

ency

(N

)

Page 11: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

• Summary:• Folate intervention study indicates a causal

relationship between folate supplementation and arsenic methylation in a folate-deficient population in Bangladesh.

• Implications:• Enhancing arsenic methylation, as achieved by

adequate folate status, could reduce arsenic-inducedhealth outcomes.

• Future research:• In a nested case-control study, we will determine if

folate deficiency is a risk factor for subsequent development of arsenic-induced skin lesions.

Page 12: Folate and Arsenic Metabolism: A double-blind placebo ... · J Occup environ Med 2003, 45:241-8 Cancer Epidemiol Biomarker Prev 1997: 589-96 Toxicol Appl Pahrmacol 2005, 206: 299-308.

Special Thanks…

Joseph GrazianoVesna Slavkovich

Marni HallOlga Balac

Michael Jerome

Mary V. GambleVesna IlievskiMerle Jalakas

EpidemiologyHabibul Ahsan

Yu ChenPamela Factor-Litvak

Environmental Health SciencesFaruque Parvez

BiostatisticsXinhua LiuDiane LevyBangladesh

Tarique IslamShafiul Alam

Mominul IslamField Staff

LamontLex van Geen